SLC1A2 and relapsing-remitting multiple sclerosis: These findings showed that relapsing RRMS patients irrespective of exposure to DMT showed higher plasma EV-EAAT2 levels than DMT-treated and untreated remitting patients and healthy controls (Fig. 6D and Table 5).